APOE4 Homozygous Alzheimer’s Disease (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
APOE4 Homozygous Alzheimer’s Disease (AD) Market Outlook Thelansis’s “APOE4 Homozygous Alzheimer’s Disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential APOE4 Homozygous Alzheimer’s Disease (AD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). APOE4 Homozygous Alzheimer’s Disease (AD) Overview Alzheimer’s disease (AD) is a progressive neurodegenerative disease associated with cognitive decline and is the most common form of dementia in the elderly. Approximately 13% of people over the age of 65 and 45% over the age of 85 are estimated to have AD. The imbalance between the production and clearance of amyloid-β (Aβ...